

Targeted Protein Degradation Forum in Japan

At Shonan iPark

<https://www.shonan-health-innovation-park.com/siteassets/pdfs/180510access-en.pdf>

August 22-23, 2019



Day-1

10:30~18:30 (Session+Exhibition)
18:30~20:00 (Dinner party)

Day-2

10:00~15:00 (Session+Exhibition)
15:00~18:00 (Partnering+Exhibition)

REGISTRATION FEE

(Full package: Conference, Lunch, Dinner, iPark tour, Partnering)

Payment received	From July 20,2019
Industry	JPY 50,000
Academia・iPark tenant	JPY 40,000

SPEAKERS



Mikihiko Naito

Chief, Division of Molecular Target and Gene Therapy Products
National Institute of Health Sciences



Gwenn M. Hansen

Vice President
Drug Discovery Technologies
Nurix Therapeutics



Behnam Nabet

Research Fellow
Dana-Farber Cancer Institute



Masato Kanemaki

Professor
National Institute of Genetics



Kanae Gamo

VP Biology
Co-Founder
FIMECS, Inc.



Michael Plewe

Vice President-
Medicinal Chemistry
Cullgen Inc.



Hyunsun Jo

Founder and CEO
Pin Therapeutics, Inc.



Yusuke Tominari

CEO/CSO
Co-Founder
FIMECS, Inc.



Taisuke Uehara

Principal Scientist
Eisai Co., Ltd.



Takumi Ito

Associate Professor
Department of Nanoparticle
Translational Research
Tokyo Medical University



Hirokazu Arimoto

Professor
Graduate School of Life
Sciences
Tohoku University

Contact

Targeted Protein Degradation
Forum in Japan (ibma,Co.,Ltd) /
Mail:summit@ibtool.jp

Registration

<https://www.ibtool.biz/tpd-forum/>



DESCRIPTION

Targeted Protein Degradation (TPD) is emerging technology. TPD is well known as Proteolysis Targeting Chimeras (PROTACs), the bi-functional molecules composed target binder with E3 ligase binder to hijack ubiquitin-proteasome system (UPS). In addition, Molecular Glue also lead to degrade the targeted proteins. Unlike conventional inhibitors, TPD has a potential to achieve the Drugging Undruggable Targets. Arvinas announced the initiation of first clinical trials of PROTACs drugs in this year. Now, researchers around the world are interested in TPD area. Therefore, this is very attractive event in terms of the deep discussion, networking with KOLs and business partnering among Academia, Pharma and service providers.

PROGRAM

DAY-1 [8/22]

9:30	Registration	
10:30~10:45	Opening remarks	
10:45~11:30	Key note : Induced protein degradation by chimeric small molecules; recent progress and outlook Mikihiko Naito <small>Chief, Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences</small>	
11:30~12:00	Presentation : RaPPIDS : Efficient discovery platform of the targeted protein degradation drugs Yusuke Tominari <small>CEO/CSO, Co-Founder FIMECS, Inc.</small>	
12:00~12:15	iPark company session : Hit compound identification for any target by high-throughput binding screening SEED SUPPLY Inc. 	
12:30~13:00	Luncheon seminar : Protein Degradation as an emerging approach for targeting kinome Carna Biosciences, Inc. 	
13:00~13:30	Networking break	
13:30~14:00	Presentation : Landscaping different E3 ligases as a platform of protein degradation therapeutics Hyunsun Jo <small>Founder and CEO Pin Therapeutics, Inc.</small>	
14:00~14:30	Presentation : Autophagy-based targeted degradation Hirokazu Arimoto <small>Professor Graduate School of Life Sciences Tohoku University</small>	
14:30~15:00	Presentation Coming soon	
15:00~15:30	Networking break	
15:30~16:00	Keynote : Leveraging the dTAG platform to degrade cancer dependencies Behnam Nabet <small>Research Fellow Dana-Farber Cancer Institute</small>	
16:00~16:30	Key note : The Auxin-Inducible-Degron System as a Tool for Target Validation Masato Kanemaki <small>Professor National Institute of Genetics</small>	
16:30~17:00	Networking break	
17:00~17:15	iPark company session : Introduction of Axcelead Axcelead Drug Discovery Partners, Inc. 	
17:15~18:30	iPark tour iPark / Axcelead Drug Discovery Partners, Inc. 	
18:30~20:00	Dinner party	

DAY-2 [8/23]

9:00	Registration	
10:00~10:45	Key note : TBD Gwenn M. Hansen <small>Vice President Drug Discovery Technologies Nurix Therapeutics</small>	
10:45~11:15	Presentation : Sulfonamide Small Molecules Target DCAF15-CUL4 Ubiquitin Ligase to Promote Selective Degradation of Splicing Factor CAPER-alpha Taisuke Uehara <small>Principal Scientist Eisai Co., Ltd.</small>	
11:15~11:45	Presentation : Molecular mechanisms of cereblon-based drugs Takumi Ito <small>Associate Professor Department of Nanoparticle Translational Research Tokyo Medical University</small>	
12:00~12:30	Luncheon seminar : TBD WuXi AppTec 	
12:30~13:00	Networking break	
13:00~13:30	Key note : Ubiquitin mediated small molecule induced target elimination (uSMITE) for cancer Michael Plewe <small>Vice President - Medicinal Chemistry Cullgen Inc.</small>	
13:30~14:00	Key note : Targeted IRAK-M degradation as a novel approach in cancer immunotherapy overcoming innate-driven immunosuppression Kanae Gamo <small>VP Biology Co-Founder FIMECS, Inc.</small>	
14:00~14:45	Panel discussion	
14:45~14:55	Closing remarks	
15:00~18:00	Partnering	

GOLD Sponsors



Sponsors



Event Partner

